Sectors
KYTX
Kyverna Therapeutics, Inc.
8.87
4 x 8.75
1 x 9.30
bid
ask
+
0.37
4.35%
100 @ 04:00 PM
8.75 -0.12 (1.35%)
| Ytd | -5.64% | |
| 1y | 168.79% |
8.64
day range
9.14
3.27
52 week range
13.67
| Open | 8.81 | Prev Close | 8.50 | Low | 8.64 | High | 9.14 | Mkt Cap | 539.25M |
| Vol | 0.00 | Avg Vol | 1.01M | EPS | -3.28 | P/E | -2.70 | Forward P/E | -1.00 |
| Beta | 1.93 | Short Ratio | 7.35 | Inst. Own | 76.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 8.08 | 200-d Avg | 8.32 | 1yr Est | 27.33 |
| Income Statement | |||
| Operating Expenses | 39.56M | ||
| Research and Development Expense | 24.79M | ||
| Selling, General and Administrative Expense | 14.77M | ||
| Operating Income | -39.56M | ||
| Interest Expense | 674.00K | ||
| Net Income | -38.32M | ||
| Net Income Common Stock | -38.32M | ||
| Net Income Common Stock (USD) | -38.32M | ||
| Consolidated Income | -38.32M | ||
| Earnings per Basic Share | -0.63 | ||
| Earnings per Basic Share (USD) | -0.63 | ||
| Earnings per Diluted Share | -0.63 | ||
| Earning Before Interest & Taxes (EBIT) | -37.65M | ||
| Earning Before Interest & Taxes (USD) | -37.65M | ||
| Weighted Average Shares | 60.90M | ||
| Weighted Average Shares Diluted | 60.90M | ||
| Balance Sheet | |||
| Cash and Equivalents | 32.36M | ||
| Cash and Equivalents (USD) | 32.36M | ||
| Investments | 167.62M | ||
| Investments Current | 167.62M | ||
| Current Assets | 206.54M | ||
| Property, Plant & Equipment Net | 9.29M | ||
| Total Assets | 219.82M | ||
| Debt Current | 1.53M | ||
| Total Debt | 33.00M | ||
| Current Liabilities | 22.80M | ||
| Debt Non-Current | 31.47M | ||
| Total Liabilities | 54.27M | ||
| Accumulated Retained Earnings (Deficit) | -502.87M | ||
| Accumulated Other Comprehensive Income | -142.00K | ||
| Shareholders Equity | 165.55M | ||
| Shareholders Equity (USD) | 165.55M | ||
| Assets Non-Current | 13.28M | ||
| Total Debt (USD) | 33.00M | ||
| Liabilities Non-Current | 31.47M | ||
| Trade and Non-Trade Payables | 2.93M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 778.00K | ||
| Net Cash Flow from Financing | 3.79M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -388.00K | ||
| Capital Expenditure | -548.00K | ||
| Issuance (Purchase) of Equity Shares | 4.14M | ||
| Issuance (Repayment) of Debt Securities | -95.00K | ||
| Net Cash Flow from Investing | 36.13M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 36.68M | ||
| Net Cash Flow from Operations | -40.31M | ||
| Share Based Compensation | 3.51M | ||